Francis Chris 4

Accession 0001193125-25-314737

CIK 0001631574other

View on SEC.gov Company Profile

Filed

Dec 9, 7:00 PM ET

Accepted

Dec 10, 9:45 PM ET

Size

41.0 KB

Accession

0001193125-25-314737

Insider Transaction Report

Form 4

Period: 2025-12-08

Wave Life Sciences Ltd.WVE

Francis Chris

See Remarks

Transactions

Exercise/Conversion
Ordinary Shares
2025-12-08$3.14/sh+28,125$88,313→ 53,125 total
Sale
Ordinary Shares
2025-12-08$14.50/sh−28,125$407,813→ 25,000 total
Exercise/Conversion
Ordinary Shares
2025-12-08$3.87/sh+107,400$415,638→ 132,400 total
Sale
Ordinary Shares
2025-12-08$14.56/sh−107,400$1,563,314→ 25,000 total
Exercise/Conversion
Ordinary Shares
2025-12-08$4.75/sh+45,882$217,940→ 70,882 total
Sale
Ordinary Shares
2025-12-08$14.50/sh−45,882$665,289→ 25,000 total
Exercise/Conversion
Ordinary Shares
2025-12-08$3.14/sh+9,375$29,438→ 34,375 total
Sale
Ordinary Shares
2025-12-08$15.00/sh−9,375$140,625→ 25,000 total
Exercise/Conversion
Ordinary Shares
2025-12-08$3.14/sh+37,500$117,750→ 62,500 total
Sale
Ordinary Shares
2025-12-08$14.08/sh−37,500$528,000→ 25,000 total
Exercise/Conversion
Ordinary Shares
2025-12-08$3.87/sh+17,900$69,273→ 42,900 total
Sale
Ordinary Shares
2025-12-08$15.00/sh−17,900$268,500→ 25,000 total
Exercise/Conversion
Ordinary Shares
2025-12-08$4.75/sh+122,349$581,158→ 147,349 total
Sale
Ordinary Shares
2025-12-08$14.20/sh−122,349$1,736,744→ 25,000 total
Exercise/Conversion
Ordinary Shares
2025-12-08$10.48/sh+50,000$524,000→ 75,000 total
Sale
Ordinary Shares
2025-12-08$16.00/sh−50,000$800,000→ 25,000 total
Exercise/Conversion
Ordinary Shares
2025-12-08$2.83/sh+22,500$63,675→ 47,500 total
Sale
Ordinary Shares
2025-12-08$14.08/sh−22,500$316,800→ 25,000 total
Exercise/Conversion
Share Option (right to buy)
2025-12-08−75,000→ 9,375 total
Exercise: $3.14Exp: 2032-01-01→ Ordinary Shares (75,000 underlying)
Exercise/Conversion
Share Option (right to buy)
2025-12-08−125,300→ 161,100 total
Exercise: $3.87Exp: 2034-02-05→ Ordinary Shares (125,300 underlying)
Exercise/Conversion
Share Option (right to buy)
2025-12-08−168,231→ 76,469 total
Exercise: $4.75Exp: 2033-02-17→ Ordinary Shares (168,231 underlying)
Exercise/Conversion
Share Option (right to buy)
2025-12-08−50,000→ 0 total
Exercise: $10.48Exp: 2031-02-01→ Ordinary Shares (50,000 underlying)
Exercise/Conversion
Share Option (right to buy)
2025-12-08−22,500→ 0 total
Exercise: $2.83Exp: 2023-07-25→ Ordinary Shares (22,500 underlying)

Footnotes (7)

[F1]The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
[F2]The share option represented a right to purchase a total of 150,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026.
[F3]The share option represented a right to purchase a total of 286,400 ordinary shares that vest as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.
[F4]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.50 to $14.78 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
[F5]The share option represented a right to purchase a total of 244,700 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
[F6]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.08 to $15.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
[F7]These share options are fully vested.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Wave Life Sciences Ltd.

CIK 0001631574

→

Entity typeother

Related Parties

filerCIK 0001657709

Filing Metadata

Form type: 4
Filed: Dec 9, 7:00 PM ET
Accepted: Dec 10, 9:45 PM ET
Size: 41.0 KB

View on SEC.gov